Sirolimus is Effective for Primary Refractory/relapsed Warm Autoimmune Haemolytic Anaemia/Evans Syndrome: a Retrospective Single-center Study

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2023 Nov 15

PMID 37967535

Authors

Zhuxin Zhang

Qinglin Hu

Chen Yang

Miao Chen

Bing Han

Affiliations

Soon will be listed here.

Abstract

Background: Some patients with warm autoimmune haemolytic anaemia (wAIHA) or Evans syndrome (ES) have no response to glucocorticoid or relapse. Recent studies found that sirolimus was effective in autoimmune cytopenia with a low relapse rate.

Methods: Data from patients with refractory/relapsed wAIHA and ES in Peking Union Medical College Hospital from July 2016 to May 2022 who had been treated with sirolimus for at least 6 months and followed up for at least 12 months were collected retrospectively. Baseline and follow-up clinical data were recorded and the rate of complete response (CR), partial response (PR) at different time points, adverse events, relapse, outcomes, and factors that may affect the efficacy and relapse were analyzed.

Results: There were 44 patients enrolled, with 9 (20.5%) males and a median age of 44 (range: 18-86) years. 37 (84.1%) patients were diagnosed as wAIHA, and 7 (15.9%) as ES. Patients were treated with sirolimus for a median of 23 (range: 6-80) months and followed up for a median of 25 (range: 12-80) months. 35 (79.5%) patients responded to sirolimus, and 25 (56.8%) patients achieved an optimal response of CR. Mucositis (11.4%), infection (9.1%), and alanine aminotransferase elevation (9.1%) were the most common adverse events. 5/35 patients (14.3%) relapsed at a median of 19 (range: 15-50) months. Patients with a higher sirolimus plasma trough concentration had a higher overall response (OR) and CR rate ( 0.009, 0.011, respectively). At the time of enrolment, patients were divided into two subgroups that relapsed or refractory to glucocorticoid, and the former had poorer relapse-free survival ( 0.032) than the other group.

Conclusion: Sirolimus is effective for patients with primary refractory/relapsed wAIHA and ES, with a low relapse rate and mild side effects. Patients with a higher sirolimus plasma trough concentration had a higher OR and CR rate, and patients who relapsed to glucocorticoid treatment had poorer relapse-free survival than those who were refractory.

Citing Articles

Roxadustat combined with immunosuppressants for treatment of pure red cell aplasia with kidney injury.

Fan L, Cao L, Luo Y, Gao F Ann Hematol. 2024; 103(12):5925-5927.

PMID: 39463184 DOI: 10.1007/s00277-024-06053-8.

Diagnostic and Therapeutic Strategies in Evans Syndrome: A Case Report and Literature Review.

Palvia A, Damera A, Magar S, Nandi A, Goyal M Cureus. 2024; 16(7):e64866.

PMID: 39156320 PMC: 11330688. DOI: 10.7759/cureus.64866.

Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.

Loriamini M, Cserti-Gazdewich C, Branch D Int J Mol Sci. 2024; 25(8).

PMID: 38673882 PMC: 11049952. DOI: 10.3390/ijms25084296.

References

Anderson D, Ali K, Blanchette V, Brouwers M, Couban S, Radmoor P . Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007; 21(2 Suppl 1):S9-56. DOI: 10.1016/j.tmrv.2007.01.001. View

Martel R, Klicius J, Galet S . Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol. 1977; 55(1):48-51. DOI: 10.1139/y77-007. View

Gurcan H, Keskin D, Stern J, Nitzberg M, Shekhani H, Ahmed A . A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2008; 9(1):10-25. DOI: 10.1016/j.intimp.2008.10.004. View

Jasinski S, Weinblatt M, Glasser C . Sirolimus as an Effective Agent in the Treatment of Immune Thrombocytopenia (ITP) and Evans Syndrome (ES): A Single Institution's Experience. J Pediatr Hematol Oncol. 2017; 39(6):420-424. DOI: 10.1097/MPH.0000000000000818. View

Feng Y, Xiao Y, Yan H, Wang P, Zhu W, Cassady K . Sirolimus as Rescue Therapy for Refractory/Relapsed Immune Thrombocytopenia: Results of a Single-Center, Prospective, Single-Arm Study. Front Med (Lausanne). 2020; 7:110. PMC: 7136762. DOI: 10.3389/fmed.2020.00110. View

Miano M, Calvillo M, Palmisani E, Fioredda F, Micalizzi C, Svahn J . Sirolimus for the treatment of multi-resistant autoimmune haemolytic anaemia in children. Br J Haematol. 2014; 167(4):571-4. DOI: 10.1111/bjh.13010. View

McMillan R, Bussel J, George J, Lalla D, Nichol J . Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2007; 83(2):150-4. DOI: 10.1002/ajh.20992. View

Maung S, Leahy M, OLeary H, Khan I, Cahill M, Gilligan O . A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. Br J Haematol. 2013; 163(1):118-22. DOI: 10.1111/bjh.12486. View

Audia S, Grienay N, Mounier M, Michel M, Bonnotte B . Evans' Syndrome: From Diagnosis to Treatment. J Clin Med. 2020; 9(12). PMC: 7759819. DOI: 10.3390/jcm9123851. View

10.

Dussadee K, Taka O, Thedsawad A, Wanachiwanawin W . Incidence and risk factors of relapses in idiopathic autoimmune hemolytic anemia. J Med Assoc Thai. 2010; 93 Suppl 1:S165-70. View

11.

Cejka D, Hayer S, Niederreiter B, Sieghart W, Fuereder T, Zwerina J . Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum. 2010; 62(8):2294-302. DOI: 10.1002/art.27504. View

12.

Wu C, Wang Q, Xu D, Li M, Zeng X . Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. Rheumatology (Oxford). 2020; 60(6):2629-2634. DOI: 10.1093/rheumatology/keaa645. View

13.

Feng X, Lin Z, Sun W, Hollinger M, Desierto M, Keyvanfar K . Rapamycin is highly effective in murine models of immune-mediated bone marrow failure. Haematologica. 2017; 102(10):1691-1703. PMC: 5622853. DOI: 10.3324/haematol.2017.163675. View

14.

Kahan B, Podbielski J, Napoli K, KATZ S, Meier-Kriesche H, Van Buren C . Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation. 1998; 66(8):1040-6. DOI: 10.1097/00007890-199810270-00013. View

15.

Teachey D, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J . Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009; 145(1):101-6. PMC: 2819393. DOI: 10.1111/j.1365-2141.2009.07595.x. View

16.

Bayram E, Pehlivan U, Fajgenbaum D, Paydas S . Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy. Am J Hematol. 2022; 98(2):361-364. PMC: 9987611. DOI: 10.1002/ajh.26783. View

17.

Huang Y, Chen M, Yang C, Ruan J, Wang S, Han B . Sirolimus is effective for refractory/relapsed/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial. Leukemia. 2022; 36(5):1351-1360. DOI: 10.1038/s41375-022-01532-1. View

18.

Hill Q, Stamps R, Massey E, Grainger J, Provan D, Hill A . The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2016; 176(3):395-411. DOI: 10.1111/bjh.14478. View

19.

Miano M, Rotulo G, Palmisani E, Giaimo M, Fioredda F, Pierri F . Sirolimus as a rescue therapy in children with immune thrombocytopenia refractory to mycophenolate mofetil. Am J Hematol. 2018; 93(7):E175-E177. DOI: 10.1002/ajh.25119. View

20.

Bass G, Tuscano E, Tuscano J . Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev. 2014; 13(4-5):560-4. DOI: 10.1016/j.autrev.2013.11.010. View